Imexpharm announced its strategic focus on high-tech pharmaceutical products and ambitious growth targets for 2026 at its Annual General Meeting of Shareholders (AGM) held on 22/4. The company aims for 3.200 billion VND in revenue, with profit indicators projected to show double-digit growth: revenue increasing by 9,8%, pre-tax profit by 12,5%, and EBITDA by 12,3% compared to the previous year.

Pharmacist Tran Thi Dao, Board Member and General Director of Imexpharm, highlighted the evolving landscape of the pharmaceutical industry. "The sector faces increasing competitive pressure, stricter standards, and narrowing profit margins," Ms. Dao stated. "While market potential remains, it is no longer easy to exploit. Growth is clearly shifting towards high-value and high-tech products." This trend necessitates a strategic shift for pharmaceutical companies, moving from "quantity growth" to "value growth."

Pharmacist Tran Thi Dao, Board Member and General Director of Imexpharm, speaking at the Imexpharm AGM on 22/4. *Photo: Imexpharm*

To realize its 2026 growth plan, Imexpharm is expanding its research and production of high-tech pharmaceuticals. A significant investment of nearly 1.500 billion VND is allocated for the construction of the Cat Khanh pharmaceutical technology zone. The company has already identified a portfolio of nearly 150 products for the new facility, with almost 50% designed for treating chronic diseases. This year is also a milestone for the company to leverage its research and production capabilities, anticipating the global wave of patent expirations and opening opportunities for biosimilar medicines.

The General Director affirmed that Imexpharm's decade-long EU-GMP foundation helps it maintain a leading market position. This foundation supports accelerated market expansion, a focus on high-value product portfolios, and enhanced operational efficiency, further strengthened by the involvement of strategic shareholders. Ms. Dao emphasized, "Technology collaboration has become a strategic direction for Imexpharm this year, helping the company improve research, access advanced technology, and strengthen long-term competitiveness."

Imexpharm leaders addressing shareholder concerns during the discussion session at the 2026 Imexpharm AGM. *Photo: Imexpharm*

Beyond new investments, Imexpharm optimizes production costs, benefiting from factories amortized over the past 10 years. The company focuses on developing high-tech products and diversifying its over-the-counter (OTC) product portfolio through expanded cooperation with modern pharmacy chains. This strategy aims to increase market penetration, especially in the Northern region. Digital transformation and ESG (Environmental, Social, and Governance) integration are also being implemented to enhance efficiency and promote sustainable development.

The company also has 160 R&D projects ready for immediate production on its four existing factory clusters. Alongside production expansion, Imexpharm emphasizes robust corporate governance. It is adopting advanced governance practices, including the corporate governance principles for public companies in Vietnam, the ASEAN Corporate Governance Scorecard, and other international standards. The early adoption of modern management systems like SAP S/4HANA Cloud Private Edition, IFRS, and the Enterprise Risk Management (ERM) model contributes to enhancing transparency, standardizing operations, and improving efficiency.

Mr. Ngo Minh Tuan (center), Deputy General Director of Operations, taking a souvenir photo with Imexpharm leaders at the 2026 AGM. *Photo: Imexpharm*

These initiatives have consistently strengthened the company's business performance. Imexpharm's Q1 results reported 629 billion VND in revenue and 103 billion VND in pre-tax profit, an 8% increase compared to the same period last year.

Yen Chi